Maricopa's Bet: MOUD Behind Bars Is Working

Maricopa County is now treating more than 400 people with medications for opioid use disorder inside its jail system — a number that would have been nearly impossible a few years ago, before opioid settlement money started flowing and before the county committed to spending it on the interventions the evidence actually supports.

The program is specific: Correctional Health Services brought on two addiction medicine specialist physicians and five addiction advanced practice providers. People entering the jail who have opioid use disorder are enrolled in the Opioid Treatment Program, where they receive buprenorphine or methadone during incarceration and — critically — are connected to community providers before they walk out. That last piece is not administrative courtesy. The first two weeks after release from incarceration are among the highest overdose-risk periods in a person’s life. They’ve been in an environment without opioids. Their tolerance has dropped. They return to a supply that’s still 70% fentanyl. People who leave jail without a connection to community MOUD services and without access to naloxone die at a rate that should constitute a public health emergency on its own.

The funding source is Maricopa County’s share of the national opioid litigation settlements — the $80 million the county will receive over 18 years from the distributors and manufacturers who helped create the crisis the MOUD program is now trying to contain. The county has received $12.5 million of that so far, and has deployed $1.5 million specifically toward this correctional health expansion. A second round of community organization grants, totaling $4.3 million across 17 organizations, was committed earlier this year.

What’s notable about the Maricopa approach is not just that it works — in-custody MOUD is one of the most evidence-supported interventions in overdose prevention, full stop — it’s that it happened at all. Correctional systems across the country have historically resisted MOUD: administrative complexity, cost, the philosophical discomfort of prescribing opioid-class medications inside jails. What Maricopa is demonstrating, with 400 enrolled patients and two addiction medicine physicians, is that those objections don’t survive contact with what the data actually says.

For Arizona, the broader context matters. The state ranks 49th out of 51 jurisdictions for behavioral health access. Fewer than one in twenty Arizonans with opioid use disorder receives buprenorphine or methadone. The jail MOUD program is not solving that problem at scale — but it is creating a warm-handoff infrastructure that connects some of the state’s highest-risk, hardest-to-reach people to the treatment system at a moment when they are, by definition, already in contact with government services.

The navigation gap — the missing link between someone who needs treatment and the facility that can provide it — is exactly what platforms like Rize Recovery exist to fill. The Maricopa program creates patients who are referred to community providers on release. Those patients need somewhere to go, and a way to find it, that doesn’t depend on knowing the right phone number or having an internet connection. Settlement dollars are building the clinical infrastructure. The navigation layer is still largely absent.

That’s the next problem to solve.